The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity. T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Kraus, Marianne, Bader, Juergen, Geurink, Paul P., Weyburne, Emily S., Mirabella, Anne C., Silzle, Tobias, Shabaneh, Tamer B., van der Linden, Wouter A., de Bruin, Gerjan, Haile, Sarah R., van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591768/
https://ncbi.nlm.nih.gov/pubmed/26069288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.109421
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados